1 **Awareness about the risk of hearing loss after ototoxic**

2 **treatments in Swiss childhood cancer survivors**

3 ## 1. Authors

4 Philippa Jörger[1,2], Carina Nigg[1], Maša Žarković[1,2], Grit Sommer[1], Martin Kompis[3],
5 Gisela Michel[4], Marc Ansari[5,6], Nicolas Waespe[1,5,7], Claudia E. Kuehni[1,7✉]
6

1.1 Affiliations

1. Institute of Social and Preventive Medicine, University of Bern, Bern,
Switzerland
2. Graduate School for Health Sciences, University of Bern, Bern,
Switzerland
3. Department of ENT, Head and Neck Surgery Inselspital, University
Hospital Bern and University of Bern, Bern, Switzerland
4. Faculty of Health Sciences and Medicine University of Lucerne, Lucerne,
Switzerland
5. CANSEARCH research platform in pediatric oncology and hematology,
Department of Pediatrics, Gynecology and Obstetrics, University of
Geneva, Geneva, Switzerland
6. Department of Women, Child and Adolescent, Division of Pediatric
Oncology and Hematology, Geneva University Hospital, University of
Geneva, Geneva, Switzerland
7. Division of Pediatric Hematology/Oncology, Department of Pediatrics,
Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
25
26
✉ **Corresponding author:**
Correspondence to:
Claudia E. Kuehni, Prof. MD;
Institute of Social and Preventive Medicine, University of Bern,
Mittelstrasse 43, 3012 Bern, Switzerland;
email: claudia.kuehni@unibe.ch; Telephone: +41 31 684 35 07
33

2. Abstract

Objectives: The International Guideline Harmonization Group recommends

childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the

risk of hearing loss. We assessed awareness among adult CCS.

Methods: We identified adults diagnosed with cancer <20 years who received

ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and

invited them to the HEAR-study. Participants completed a questionnaire and

underwent pure-tone audiometry. Cancer and treatment data came from the

ChCR. We used logistic regression to explore factors influencing awareness.

Results: 105 of 424 invited CCS participated (25%). 57% did not remember

receiving information on hearing loss prior to the study. CCS who remembered

being informed were more likely diagnosed after 1995 (OR: 4.5, 95% CI: 1.3-

15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-

13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus

cranial radiotherapy only. 44% of participants presented clinically relevant

hearing loss.

Conclusions: Over half of CCS exposed to ototoxic treatments were unaware of

their risk of hearing loss.

Practice Implications: Educating CCS about potential late effects of ototoxic

treatments is important to allow early diagnosis and treatment, especially for

those who had cancer longer ago and those exposed to cranial radiation.

Keywords (7): hearing problems, childhood cancer survivors, awareness, late-

effects, ototoxicity, information provision

Highlights:

• Half of CCS exposed to ototoxic treatment were unaware of the risk of

hearing loss

• CCS treated before 1995 were less aware about the risk of hearing loss

• Information provision is key to effective monitoring and early intervention

3. Introduction

Childhood cancer survivors (CCS) are at risk of hearing loss as a late effect of

certain treatments [1]. Forty percent of CCS treated with platinum chemotherapy,

around 20% of those treated with doses of cranial radiation ≥ 30 gray (Gy), and

varying proportions of those treated with surgery involving the auditory system

experience hearing loss [1–6]. Cumulative incidence of hearing loss due to these

treatments increases up to 15 years after completing cancer treatment [7].

Among CCS, undetected hearing loss can impair language development, school

performance, neurocognitive functions, and overall quality of life [8–11]. Regular

audiometric screening enables hearing loss to be detected as early as possible

and allows appropriate measures to be initiated. The International Guideline

Harmonization Group (IGHG) recommends that CCS treated with a known

ototoxic treatment (cisplatin with or without high-dose carboplatin (> 1500

mg/m²), and/or head or brain radiotherapy ≥ 30 Gy) and their health-care

providers "should be aware of the risk of hearing loss" [1]. IGHG recommends

annual hearing tests until six years of age, biannual tests until twelve years, and

every five years thereafter [1].

Informing CCS about the risk for late effects related to their cancer treatment is

important to facilitate follow-up care and to manage long-term health [12,13].

Previous research in Switzerland suggests CCS have limited knowledge about

their risks for late effects [14–16]. Studies investigating information provision on

specific late effects, such as hearing loss, are lacking.

Using data from the HEAR-study, a health service research project on the

hearing of CCS, we first examined whether adult CCS who had received ototoxic

treatments were aware of their risk for hearing loss, and had had their hearing

evaluated as recommended. Second, we compared CCS who were aware of

hearing loss risk with those who were not to identify CCS at increased need for

information and support. Third, we investigated whether CCS currently

experience clinically relevant hearing loss and explored the associations between

awareness, hearing evaluation after end of treatment, and current hearing loss

based on audiometric testing.

4. Methods

4.1 Study population

Eligible CCS were identified through the Swiss Childhood Cancer Registry

(ChCR). The ChCR is a national registry that includes all Swiss residents

diagnosed with leukemias, lymphomas, central nervous system (CNS) tumors,

malignant solid tumors, or Langerhans cell histiocytosis before 20 years of age

since 1976 [17,18]. We included CCS registered in the ChCR who had survived

at least two years since diagnosis, had received ototoxic treatment as defined

per IGHG guidelines, and were ≥ 18 years at the time of study. We excluded

CCS who lacked a valid address, were living outside Switzerland, did not speak

German or French, and had been contacted for another study in the past six

months (January 2022-July 2022). The Ethics Committee of the Canton of Bern

approved the ChCR (166/2014) and the HEAR-study (2021-01624).

4.2 Procedures and study design

The HEAR-study is a health service research project set up in 2021 at the

University of Bern, Switzerland. Details have been published previously [19].

Eligible CCS were invited by postal mail; we sent up to three reminders to CCS

who did not respond. CCS who responded with informed consent received an e-

mail request to complete an online questionnaire (Supplementary Table S6) and

an invitation to attend a free hearing test. Participants performed hearing tests at

a local hearing aid shop where a certified acoustician performed bilateral pure-

tone audiometry (125-8000Hz) with an additional bone conduction measurement

(250-4000Hz) if the hearing threshold was > 25dB. We collected questionnaires

and audiograms between July 15, 2022, and July 15, 2023.

4.3 Hearing-related information

4.3.1 Awareness about the risk of hearing loss and information on prior

hearing evaluations

We assessed awareness about the risk of hearing loss using a questionnaire.

We asked participants if they had been informed about an increased risk of

hearing loss (yes/no/don't know). We also asked if they had been counseled to

monitor their hearing after end of treatment (yes/no/don't know). If participants

answered yes to either of the two questions, we coded being informed as "yes".

Further, we asked if their hearing had ever been evaluated after end of treatment

(yes/no/don't know).

4.3.2 Self-reported hearing loss, perceived hearing difficulties, and other late

effects

We asked participants if they experienced any late effects of cancer or its therapy

(yes/no), and to list them. We created a variable "late effects other than hearing

loss" (yes/no) for which "no" indicated participants who only listed hearing loss or

nothing. If participants listed hearing loss as a late effect in the open question,

the variable on self-reported hearing loss was coded as "yes". Further, we asked

if they had problems following a conversation when there was background noise

(hearing difficulties in noisy environments) (yes/no) and if they felt they did not

hear well (feeling of poor hearing) (yes, often/yes, sometimes/no).

4.3.3 Hearing loss from audiogram measurements

The hearing aid shops sent us audiogram results in a coded file. For grading we

visualized the audiograms using the R package "audiometry" (Lehnbert B, R

package version 0.3.0, 2021) in RStudio (R Core Team, Vienna, AUT, 2022).

Two trained researchers (PJ and CN) independently graded audiograms for each

ear according to the SIOP Boston Ototoxicity Scale [20], an established grading

scheme used for CCS exposed to ototoxic treatments [21,22]. We resolved

discrepancies through discussions with an experienced audiologist (MK). We

considered bone conduction measurements when there was consistently a

significant difference between air and bone conduction measurements (≥ 10 dB),

indicating a potential conductive hearing loss [20]. We used the grading of the

more affected ear. Severity was graded as (a) none (grade 0), (b) mild (grade 1),

(c) moderate (grade 2), or (d) severe hearing loss ($\geq$ grade 3) [20]. Clinically

relevant hearing loss was defined as SIOP Boston grade ≥ 2 [20,22].

4.4 Participant characteristics

4.4.1 Clinical and cancer-treatment related characteristics

The ChCR provided data on biological sex, year of birth, cancer diagnosis, age at

diagnosis, year of diagnosis, and type of therapy including carboplatin

chemotherapy, cisplatin chemotherapy, and cranial radiation.

4.4.2 Information on follow-up care

165 We asked participants in the questionnaire if they were still undergoing clinical

166 follow-up care related to their cancer (yes/no), and if they had received any

167 information regarding follow-up care in general (yes/no/don't know).

4.4.3 Socioeconomic characteristics

The questionnaire assessed sociodemographic characteristics including

migration background (yes/no), participants' and their parents' education levels,

and language region (German/French). Participants were categorized as having

a migration background if at least one parent was born outside Switzerland. We

defined three education level categories: primary schooling (compulsory

schooling only, ≤ 9 years), secondary education (vocational training, upper

secondary education), and tertiary education (university, or technical college).

4.5 Statistical analysis

First, we assessed how many CCS were aware of a risk of hearing problems

(information status) and how many had completed a hearing evaluation after the

end of treatment. For further analysis, we combined the categories "no" and

"don't know" interpreting both as insufficient awareness. Next, we assessed

severity of hearing loss and prevalence of clinically relevant hearing loss (SIOP

Boston Grade ≥ 2). Using univariable logistic regression, we investigated factors

associated with information status and having completed a hearing evaluation

after end of treatment (Supplementary Tables S4 and S5). We included sex, age

at study, time since diagnosis, age at diagnosis, year of diagnosis, language

region, participant and parental education, migration background, presence of

late effects other than hearing loss, self-reported hearing loss, general

information received on follow-up care, attending regular follow-up care visits,

and treatment (only platinum/only cranial radiation ≥ 30 Gy/both platinum and

cranial radiation) as explanatory variables. We categorized year of diagnosis into

the periods before and after 1995, reflecting a cut-off after which a decline in

hearing loss was observed in previous studies of CCS from Switzerland [7].

Information status was included as an additional explanatory variable for the

outcome hearing evaluation. In a multivariable logistic regression, we included all

exposures associated with the outcome at a significance level of $p \leq 0.1$. If there

were missing values in independent or dependent variables, we performed

complete case analyses.

5. Results

5.1 Study population

Of 573 eligible CCS exposed to ototoxic treatments, identified through the ChCR,

424 were invited to the study. One-hundred and five (25%) consented and

completed the questionnaire and 83 (20%) also completed a hearing test as part

of our study (Supplementary Figure SF1). About half (n=57, 54%) of participants

were female, median age at study start was 32 years (interquartile range [IQR]:

24-37), age at diagnosis 8 years (IQR: 4-13), and median time since diagnosis

23 years (IQR: 19-32) (Table 1). Common diagnoses were malignant bone

tumors (n=24, 23%), CNS tumors (n=23, 22%) and soft tissue sarcomas (n=22,

21%). Eighty CCS (76%) had been treated with platinum chemotherapy, and 41

(39%) with cranial radiation (Supplementary Table S2). Compared to

nonparticipants, CCS completing the questionnaire were more often female,

older at time of study, and further away from diagnosis (Supplementary Table

S1).

225   **TABLE 1** Characteristics of participants completing the questionnaire (N=105).

	Completed questionnaire N=105
	n (%)
Sex	
Female	57 (54)
Male	48 (46)
Age at study, years (Median, IQR)	32 (24-37)
Year of diagnosis (Median, range)	1998 (1977-2018)
1977-1995	41 (39)
1996-2005	46 (44)
2006-2018	18 (17)
Time since diagnosis, years (Median, IQR)	23 (19-32)
Age at cancer diagnosis, years (Median, IQR)	8 (4-13)
Diagnostic group of primary neoplasm (ICCC-3)	
Leukemias	0 (0)
Lymphomas	7 (7)
CNS tumors	23 (22)
Neuroblastoma	13 (12)
Retinoblastoma	3 (3)
Renal tumors	2 (2)
Hepatic tumors	4 (4)
Malignant bone tumors	24 (23)
Soft tissue sarcomas	22 (21)
Germ cell tumors	7 (7)
Other	0 (0)
Platinum Chemotherapy	
No platinum chemotherapy	23 (22)
Cisplatin	42 (40)
Carboplatin	17 (16)
Cisplatin & Carboplatin	21 (20)
Unknown	2 (2)
Cranial radiation	
No cranial radiation	64 (61)
<30 Gray	0 (0)
≥30 Gray	41 (39)
Unknown	0 (0)
Education	
Primary schooling	5 (5)
Secondary education	57 (54)
Tertiary education	43 (41)

226
227   Abbreviations: IQR, Interquartile range. n, number. ICCC-3, international classification of
228   childhood cancer, edition 3
229

5.2 Information status and prior hearing evaluation

Among 105 participants, 46 (44%, 95% confidence interval [CI]: 35-54%)

reported having received information or advice regarding risk of hearing loss or

necessity of conducting hearing tests after end of treatment, while 31 (30%, 95%

CI: 22-39%) reported not having received information/advice and 28 (27%, 95%

CI: 19-36%) did not remember (Figure 1). Similarly, 40 (38%, 95% CI: 29-48%)

participants reported having completed a hearing evaluation after end of

treatment, 34 (32%, 95% CI: 24-42%) reported not having completed a hearing

evaluation, and 31 (30%, 95% CI: 22-39%) did not remember. Of the 40

participants reporting a hearing evaluation, 13 (33%) had done it in the last 5

years, 12 (30%) longer ago, and 15 (38%) did not remember the year of their last

hearing evaluation (Supplementary Table S3).

We visualized the relationship between information status and prior hearing

evaluation using a proportional Venn diagram (Figure 1). Most CCS who were

informed also had their hearing evaluated at some point after treatment.

5.3 Degree of hearing loss and information status, self-reported hearing

loss, and prior hearing evaluation

Of 83 participants who completed a hearing test for the study, 29 had normal

hearing (35%, 95% CI: 25-46), 17 (20%, 95% CI: 13-31%) had mild, 11 (13%,

95% CI: 7-23%) moderate, and 26 (31%, 95% CI: 22-42%) severe hearing loss,

resulting in 37 participants (45%, 95% CI: 34-56%) with clinically relevant hearing

loss. Among the 36 participants with clinically relevant hearing loss who

completed the questionnaire, 20 (56%, 95% CI: 39-71%) reported having

received information/advice regarding their risk for hearing loss and 14 (39%,

95% CI: 24-56%) reported having had their hearing evaluated after end of

treatment. Further, 19 (53%, 95% CI: 36-69%) of the participants with clinically

relevant hearing loss reported prior hearing problems in the questionnaire, 29

(81%, 95% CI: 64-91%) reported hearing difficulties in noisy environments, and

30 (83%, 95% CI: 67-93%) sometimes or often felt like they were not hearing

well. (Figure 2)

5.4 Factors associated with information status and hearing evaluation

after end of treatment

Participants informed about risk of hearing loss were diagnosed more often after

1995 (odds ratio [OR]: 4.5, 95% CI: 1.3-15.4), reported more prior hearing

problems (OR: 10.9, 95% CI: 2.6-45.1) and other late effects (OR: 4.1, 95% CI:

1.3-13.2), and were more often treated with platinum chemotherapy (OR: 10.8,

95% CI: 2.2-53.2) or both platinum chemotherapy and cranial radiotherapy (OR:

6.5, 95% CI: 1.0-41.8) compared to cranial radiotherapy alone (Table 2). Those

who were informed were more likely to have had their hearing evaluated after

end of treatment (OR: 13.6, 95% CI: 3.8-48.3).

277   **TABLE 2** Factors associated with a) having received information/advice about

278   hearing loss, and b) having ever completed a hearing evaluation after therapy;

279   results from multivariable regressions.

Multivariable (95%-CI)	Informed/Advised[a,b]	Hearing evaluated[a,b]
	N=102	N=102
	OR (95%-CI)	*OR (95%-CI)*
Period of cancer diagnosis		
≤1995	1.0	1.0
>1995	**4.5 (1.3-15.4)**	2.2 (0.6-8.5)
Late effects other than hearing loss		
No	1.0	1.0
Yes	**4.1 (1.3-13.2)**	2.8 (0.8-9.6)
Self-reported hearing loss		
No	1.0	1.0
Yes	**10.9 (2.6-45.1)**	0.7 (0.2-2.7)
Maternal education		
Primary or secondary education	1.0	1.0
Tertiary education	1.7 (0.5-5.5)	1.6 (0.5-5.3)
General information received on follow-up care		
No	1.0	1.0
Yes	1.1 (0.4-3.3)	1.3 (0.4-4.4)
Information/advice received on hearing loss and hearing screening		
No	‡	1.0
Yes	‡	**13.6 (3.8-48.3)**
Regular visit of follow-up care		
No	1.0	1.0
Yes	1.9 (0.6-6.6)	1.0 (0.2-3.8)
Treatment group		
Cranial radiation ≥30 Gray only	1.0	1.0
Platinum Chemotherapy only	**10.8 (2.2-53.2)**	1.8 (0.3-9.4)
Both	**6.5 (1.0-41.8)**	0.9 (0.1-6.4)

The respective multivariable model was adjusted for variables with a p-value of 0.1 or
less in the univariable logistic regression.
[a], People with missing maternal education and missing treatment group were excluded
from the logistic regression (n=3).
[b], Age at study start and years since diagnosis were omitted from multivariable
regression for collinearity with year of diagnosis.
‡, Exposure equal to outcome
Abbreviations: CI, Confidence Interval. OR, Odds Ratio. n, number.
289

6. Discussion and Conclusion

6.1 Summary of findings

This study found that over half of CCS who received ototoxic treatment reported

they were unaware of the risk of hearing loss even though international

guidelines recommend that they be aware. More than half did not remember

having ever had their hearing evaluated after end of treatment. We found a

strong association between being informed and having had a hearing evaluation.

Almost half of participants had clinically relevant hearing loss assessed by pure-

tone audiometry, yet almost half of those did not report hearing problems in the

questionnaire, which suggests they were not aware of their hearing loss.

6.2 Information status

Previous surveys on information provision and information needs among Swiss

CCS show that approximately one-third of survivors do not remember having

ever received general information about potential late effects of their cancer or

therapy, and about 80% of CCS wish to be better informed [14–16]. In this study,

56% of CCS did not remember receiving information about the risk for hearing

loss. This is comparable to a Norwegian study about information provision in

which up to 60% of cancer survivors overall did not recall receiving information

on late effects including hearing loss, though the study also included survivors

without ototoxic treatments [12]. A study from Hong Kong assessing knowledge

about risk-based, exposure-related late effects found that, similar to our study,

almost 60% of CCS were not aware of potential hearing problems following

ototoxic treatments [13].

6.2.1 Associations with information status

Consistent with other studies [12,14,15], we found that CCS seem to be less well

informed the more time has passed since diagnosis. A reason for this might be

that parents of patients who were younger children were the primary recipients of

information [23]. Parents might not have passed on the information to their

children, or CCS may have forgotten it given a long median time of 22 years

since diagnosis.

We found that CCS diagnosed after 1995 were better informed, which is likely

due to advances in knowledge about long-term effects of ototoxic treatments. For

example, the American Speech-Language-Hearing Association (ASHA) guideline

from 1994 recommended monitoring the hearing at least until one year post-

treatment with platinum agents and only longer if hearing loss was detected [24].

Considering that one-third of our study population was diagnosed before 1995,

they likely received outdated or limited information about potential long-term

effects.

The 1994 ASHA guideline further stated that cranial radiation alone has little

effect on hearing [24], and many clinicians might be less aware of the effect of

cranial radiation on hearing than platinum chemotherapy. This might explain why

participants who received cranial radiation ≥ 30 Gy alone were less informed

than participants treated with platinum agents. This aligns with a previous record-

based study in which we found that CCS treated with cranial radiation ≥ 30 Gy

were less likely to have received post-therapy hearing evaluations than CCS

treated with platinum chemotherapy [25]. Participants reporting other late effects

were more informed about the risk of hearing loss, suggesting that CCS with

multiple late effects are generally more aware of treatment-related complications

[26].

6.3 Hearing evaluations after end of treatment

A retrospective, record-based study examining audiological evaluations post-

therapy in Switzerland found that 28% of CCS at risk for hearing loss had not had

any hearing evaluations after end of treatment [25]. This is comparable to the

32% observed in our study. In our study, a further 30% did not recall undergoing

any hearing evaluations. While they might have had an initial test, CCS may not

have had subsequent assessments when their hearing test result was normal as

specified in older ASHA and Children's Oncology Group Long-Term Follow-Up

Guidelines [24,27]. Given that initial hearing tests often occur during or soon after

treatment, many may have forgotten about them or were not contacted for later

hearing evaluations as currently recommended [1].

6.4 Degree of hearing loss and self-reported hearing loss

We previously reported that 36% of CCS had clinically relevant hearing loss after

platinum-based therapy according to the SIOP Boston ototoxicity scale [28]. This

new study finds a higher prevalence (47%) of clinically relevant hearing loss,

likely because of different characteristics of the study population, which now is

older and further from diagnosis and more recently represents the survivor

cohort. Considering the newer study's low response rate, selection bias could

have also played a role in the difference.

Almost half of our study participants with clinically relevant hearing loss did not

report hearing problems as late effects in the questionnaire, suggesting they

were not aware of them. The proportion of participants with hearing problems by

SIOP Boston grade who did not self-report hearing loss was higher than that

found in a previous study in which we compared questionnaire-reported hearing

loss with audiometry results [29]. In that study, only 14% of CCS who did not self-

report hearing loss had hearing loss in the SIOP-Boston grade range from 1 to 4.

In the current study, self-reported hearing loss was assessed using an open

question about known late effects. We have potentially underestimated the

proportion of participants who are aware about their hearing loss since some

participants with hearing loss may not have listed it as a late effect.

6.5 Strengths and limitations

A strength of this study is the population-based sample with comprehensive

cancer-related medical data provided by the Swiss ChCR. Combined with the

questionnaire-based information and recent audiograms, our dataset allowed for

a thorough analysis. Study limitations include the response rate of 25% which, as

noted above, potentially introduced a selection bias. However, although analyses

revealed some statistically significant differences between responders and

nonresponders regarding cancer-related characteristics, differences were modest

based upon effect sizes. The low response rate may be due to the study settings

as CCS had not only to return a questionnaire but also visit a hearing aid shop

for a hearing test.

6.6 Conclusion

A large proportion of CCS are not aware of the potential risk of hearing loss due

to their treatment. Among those who are aware of this late effect, most have

undergone hearing evaluations. From this we conclude that knowledge is key to

timely interventions that can mitigate the effects of hearing loss. Caregivers,

parents, and CCS should always have the latest information on late effects and

follow-up care at hand to manage and protect auditory health throughout the lives

of CCS—even those with decades intervening since treatment.

6.7 Practice implications

How do we best manage survivorship to follow up treatment and address

potential late effects? In addition to direct, clinical support of CCS and parents,

electronic patient records continue to evolve and will improve the retention and

support the acquisition of knowledge accessible by both providers and patients.

A specific proposal for enhancing information access and retention for CCS is the

Survivorship Passport, or SurPass [30]. This tool can provide crucial details

about a survivor's medical history and a tailored plan for follow-up to caregivers,

and information for CCS that can inform their own decision-making; accessible

online, it can be continually updated by new research findings. Highly secure yet

accessible electronic records such as the SurPass can sustain awareness

among caregivers and CCS wherever their journey through survivorship takes

them.

7. Abbreviations

ASHA   American Speech-Language-Hearing Association

CCS   Childhood cancer survivor

COG   Children's Oncology Group

CI   Confidence interval

IQR   Interquartile range

Gy   Gray

8. Acknowledgements

We thank the study team of the Childhood Cancer Research Group, Institute of

Social and Preventive Medicine, University of Bern, the Swiss Childhood Cancer

Survivor Study, and the team of the Swiss Childhood Cancer Registry. We thank

Christopher Ritter from the editorial service of the Institute of Social and

Preventive Medicine at the University of Bern for the editorial suggestions. We

thank all childhood cancer survivors participating in the study.

9. CRediT authorship contribution statement

Philippa Jörger: formal analysis, investigation, writing—original draft, review & editing, visualization, project administration. **Carina Nigg:** formal analysis, writing—original draft, review & editing, supervision. **Maša Žarković**: formal analysis, writing—original draft, review & editing. **Grit Sommer:** writing—review & editing. **Martin Kompis:** formal analysis, writing—review & editing, funding acquisition. **Gisela Michel:** writing—review & editing, funding acquisition. **Marc Ansari**: conceptualization, writing—review & editing, supervision, funding acquisition. **Nicolas Waespe:** writing—review & editing, funding acquisition. **Claudia Kuehni:** conceptualization, methodology, formal analysis, writing—review & editing, supervision, project administration, funding acquisition.

10. Funding sources

This work was financially supported by the Swiss Cancer League and Swiss Cancer Research (grant number HSR-4951-11-2019, KLS/KFS-5711-01-2022, and KFS-5302-02-2021). The CANSEARCH foundation, Kinderkrebs Schweiz Foundation, and Zoé4Life Foundation supported NW.

11. Declaration of competing interest

Nicolas Waespe reports a relationship with Swedish Orphan Biovitrum AB that includes advisory board membership, consulting, and travel reimbursement and a relationship with Novartis that includes advisory board membership. None of these relationships are in association with the current study.

12.   References

[1]   E. Clemens, M.M. van den Heuvel-Eibrink, R.L. Mulder, L.C.M. Kremer,

M.M. Hudson, R. Skinner, L.S. Constine, J.K. Bass, C.E. Kuehni, T.

Langer, E.C. van Dalen, E. Bardi, N.-X. Bonne, P.R. Brock, B. Brooks, B.

Carleton, E. Caron, K.W. Chang, K. Johnston, K. Knight, P.C. Nathan, E.

Orgel, P.K. Prasad, J. Rottenberg, K. Scheinemann, A.C.H. de Vries, T.

Walwyn, A. Weiss, A. Am Zehnhoff-Dinnesen, R.J. Cohn, W. Landier,

International   Guideline   Harmonization   Group   ototoxicity   group,

Recommendations for ototoxicity surveillance for childhood, adolescent,

and young adult cancer survivors: a report from the International Late

Effects   of   Childhood   Cancer   Guideline   Harmonization   Group   in

collaboration with the PanCare Consortium., Lancet Oncol 20 (2019) e29–

e41. https://doi.org/10.1016/S1470-2045(18)30858-1.

[2]   L.K. Dillard, L. Lopez-Perez, R.X. Martinez, A.M. Fullerton, S. Chadha,

C.M. McMahon, Global burden of ototoxic hearing loss associated with

platinum-based cancer treatment: A systematic review and meta-analysis.,

Cancer   Epidemiol   79   (2022)   102203.

https://doi.org/10.1016/j.canep.2022.102203.

[3]   B. Murphy, A. Jackson, J.K. Bass, D.S. Tsang, C.M. Ronckers, L. Kremer,

S. Baliga, A. Olch, A.H. Zureick, K.-W. Jee, L.S. Constine, T.I. Yock,

Modeling the Risk of Hearing Loss From Radiation Therapy in Childhood

Cancer Survivors: A PENTEC Comprehensive Review., Int J Radiat Oncol

Biol Phys 119 (2024) 446–456. https://doi.org/10.1016/j.ijrobp.2023.08.016.

[4]   D.L. Kwong, W.I. Wei, J.S. Sham, W.K. Ho, P.W. Yuen, D.T. Chua, D.K.

470   Au, P.M. Wu, D.T. Choy, Sensorineural hearing loss in patients treated for

471   nasopharyngeal carcinoma: a prospective study of the effect of radiation

472   and cisplatin treatment., Int J Radiat Oncol Biol Phys 36 (1996) 281–9.

473   https://doi.org/10.1016/s0360-3016(96)00302-1.

474   [5]   J.K. Bass, C.-H. Hua, J. Huang, A. Onar-Thomas, K.K. Ness, S. Jones, S.

475   White, S.P. Bhagat, K.W. Chang, T.E. Merchant, Hearing Loss in Patients

476   Who Received Cranial Radiation Therapy for Childhood Cancer., J Clin

477   Oncol 34 (2016) 1248–55. https://doi.org/10.1200/JCO.2015.63.6738.

478   [6]   G.B. Williams, L.E. Kun, J.W. Thompson, H.J. Gould, R.M.S. Stocks,

479   Hearing loss as a late complication of radiotherapy in children with brain

480   tumors.,   Ann   Otol   Rhinol   Laryngol   114   (2005)   328–31.

481   https://doi.org/10.1177/000348940511400413.

482   [7]   A. Weiss, G. Sommer, R. Kasteler, K. Scheinemann, M. Grotzer, M.

483   Kompis, C.E. Kuehni, Swiss Pediatric Oncology Group (SPOG), Long-term

484   auditory complications after childhood cancer: A report from the Swiss

485   Childhood Cancer Survivor Study., Pediatr Blood Cancer 64 (2017) 364–

486   373. https://doi.org/10.1002/pbc.26212.

487   [8]   J.K. Bass, W. Liu, P. Banerjee, T.M. Brinkman, D.A. Mulrooney, A. Gajjar,

488   A.S. Pappo, T.E. Merchant, G.T. Armstrong, D. Srivastava, L.L. Robison,

489   M.M. Hudson, K.R. Krull, Association of Hearing Impairment With

490   Neurocognition in Survivors of Childhood Cancer., JAMA Oncol 6 (2020)

491   1363–1371. https://doi.org/10.1001/jamaoncol.2020.2822.

[9]   A. Weiss, G. Sommer, C. Schindera, L. Wengenroth, A. Karow, M. Diezi,

G. Michel, C.E. Kuehni, Swiss Paediatric Oncology Group (SPOG),

Hearing loss and quality of life in survivors of paediatric CNS tumours and

other   cancers.,   Qual   Life   Res   28   (2019)   515–521.

https://doi.org/10.1007/s11136-018-2021-2.

[10] M. Khairi Md Daud, R.M. Noor, N.A. Rahman, D.S. Sidek, A. Mohamad,

The effect of mild hearing loss on academic performance in primary school

children.,   Int   J   Pediatr   Otorhinolaryngol   74   (2010)   67–70.

https://doi.org/10.1016/j.ijporl.2009.10.013.

[11] S. Strebel, K. Baust, D. Grabow, J. Byrne, T. Langer, A. Am Zehnhoff-

Dinnesen, R. Kuonen, A. Weiss, T. Kepak, J. Kruseova, C. Berger, G.

Calaminus, G. Sommer, C.E. Kuehni, PanCareLIFE Consortium, Auditory

complications among childhood cancer survivors and health-related quality

of life: a PanCareLIFE study., J Cancer Surviv (2023) 1–12.

https://doi.org/10.1007/s11764-023-01456-4.

[12] M.E. Gianinazzi, C.E. Kiserud, E. Ruud, H.C. Lie, Who Knows? Information

Received, and Knowledge about, Cancer, Treatment and Late Effects in a

National Cohort of Long-Term Childhood, Adolescent and Young Adult

Cancer   Survivors.,   Cancers   (Basel)   14   (2022)   1534.

https://doi.org/10.3390/cancers14061534.

[13] C.-T. Ma, H.W. Chou, T.T.-N. Lam, Y.T. Tung, Y.W. Lai, L.-K. Lee, V.W.-Y.

Lee, N.C.-Y. Yeung, A.W.-K. Leung, S. Bhatia, C.K. Li, Y.T. Cheung,

Provision of a personalized survivorship care plan and its impact on

cancer-related health literacy among childhood cancer survivors in Hong

Kong.,   Pediatr   Blood   Cancer   70   (2023)   e30084.

https://doi.org/10.1002/pbc.30084.

[14] M.E. Gianinazzi, S. Essig, C.S. Rueegg, N.X. von der Weid, P. Brazzola,

C.E. Kuehni, G. Michel, Swiss Paediatric Oncology Group (SPOG),

Information provision and information needs in adult survivors of childhood

cancer.,   Pediatr   Blood   Cancer   61   (2014)   312–8.

https://doi.org/10.1002/pbc.24762.

[15] S. Christen, E. Weishaupt, J. Vetsch, C.S. Rueegg, L. Mader, S. Dehler, G.

Michel, Perceived information provision and information needs in

adolescent and young adult cancer survivors., Eur J Cancer Care (Engl) 28

(2019) e12892. https://doi.org/10.1111/ecc.12892.

[16] Y. Sievers, K. Roser, K. Scheinemann, G. Michel, A. Ilic, The information

needs of relatives of childhood cancer patients and survivors: A systematic

review of quantitative evidence., Patient Educ Couns 126 (2024) 108316.

https://doi.org/10.1016/j.pec.2024.108316.

[17] Childhood Cancer Registry, Childhood Cancer Registry (ChCR), (2023).

https://www.childhoodcancerregistry.ch/ (accessed August 1, 2023).

[18] G. Michel, N.X. von der Weid, M. Zwahlen, M. Adam, C.E. Rebholz, C.E.

Kuehni, Swiss Childhood Cancer Registry, Swiss Paediatric Oncology

Group (SPOG) Scientific Committee, The Swiss Childhood Cancer

Registry: rationale, organisation and results for the years 2001-2005.,

Swiss   Med   Wkly   137   (2007)   502–9.

https://doi.org/10.4414/smw.2007.11875.

[19]   P. Jörger, C. Nigg, L. Mader, S. Strebel, M. Kompis, Z. Tomášiková, C.

Schindera, G. Michel, N.X. Von Der Weid, M. Ansari, N. Waespe, C.E.

Kuehni, Protocol for a low-threshold screening program to detect hearing

loss in childhood cancer survivors in Switzerland: The HEAR-study, JMIR

Preprints (2024). https://doi.org/10.2196/preprints.63627.

[20]   P.R. Brock, K.R. Knight, D.R. Freyer, K.C.M. Campbell, P.S. Steyger, B.W.

Blakley, S.R. Rassekh, K.W. Chang, B.J. Fligor, K. Rajput, M. Sullivan,

E.A. Neuwelt, Platinum-induced ototoxicity in children: a consensus review

on mechanisms, predisposition, and protection, including a new

International Society of Pediatric Oncology Boston ototoxicity scale., J Clin

Oncol 30 (2012) 2408–17. https://doi.org/10.1200/JCO.2011.39.1110.

[21]   A. Khan, A. Budnick, D. Barnea, D.R. Feldman, K.C. Oeffinger, E.S.

Tonorezos, Hearing Loss in Adult Survivors of Childhood Cancer Treated

with   Radiotherapy.,   Children   (Basel)   5   (2018)   59.

https://doi.org/10.3390/children5050059.

[22]   D.J. Moke, C. Luo, J. Millstein, K.R. Knight, S.R. Rassekh, B. Brooks,

C.J.D. Ross, M. Wright, V. Mena, T. Rushing, A.J. Esbenshade, B.C.

Carleton, E. Orgel, Prevalence and risk factors for cisplatin-induced

hearing loss in children, adolescents, and young adults: a multi-institutional

North American cohort study., Lancet Child Adolesc Health 5 (2021) 274–

283. https://doi.org/10.1016/S2352-4642(21)00020-1.

[23] S. Palmer, A. Mitchell, K. Thompson, M. Sexton, Unmet needs among

adolescent cancer patients: a pilot study., Palliat Support Care 5 (2007)

127–34. https://doi.org/10.1017/s1478951507070198.

[24] American Speech-Language-Hearing Association, Audiologic Management

of   Individuals   Receiving   Cochleotoxic   Drug   Therapy,   (1994).

https://doi.org/10.1044/policy.GL1994-00003.

[25] A. Weiss, R. Kuonen, H. Brockmeier, M. Grotzer, C. Candreia, R. Maire, P.

Senn, C. Stieger, J. Rosenfeld, D. Veraguth, M. Kompis, K. Scheinemann,

C.E. Kuehni, Swiss Pediatric Oncology Group (SPOG), Audiological

monitoring in Swiss childhood cancer patients., Pediatr Blood Cancer 65

(2018) e26877. https://doi.org/10.1002/pbc.26877.

[26] C. Signorelli, C.E. Wakefield, J.E. Fardell, W.H.B. Wallace, E.G.

Robertson, J.K. McLoone, R.J. Cohn, The impact of long-term follow-up

care for childhood cancer survivors: A systematic review., Crit Rev Oncol

Hematol   114   (2017)   131–138.

https://doi.org/10.1016/j.critrevonc.2017.04.007.

[27] Children's Oncology Group, Long-Term Follow-Up Guidelines for Survivors

of Childhood, Adolescent, and Young Adult Cancers - Version 4.0, (2013).

www.survivorshipguidelines.org (accessed February 15, 2024).

[28] S. Strebel, L. Mader, T. Sláma, N. Waespe, A. Weiss, R. Parfitt, A. Am

Zehnhoff-Dinnesen, M. Kompis, N.X. von der Weid, M. Ansari, C.E.

Kuehni, Severity of hearing loss after platinum chemotherapy in childhood

cancer   survivors., Pediatr   Blood   Cancer   69   (2022)   e29755.

https://doi.org/10.1002/pbc.29755.

[29] A. Weiss, G. Sommer, R. Kuonen, K. Scheinemann, M. Grotzer, M.

Kompis, C.E. Kuehni, Swiss Paediatric Oncology Group (SPOG),

Validation of questionnaire-reported hearing with medical records: A report

from the Swiss Childhood Cancer Survivor Study., PLoS One 12 (2017)

e0174479. https://doi.org/10.1371/journal.pone.0174479.

[30] R. Haupt, S. Essiaf, C. Dellacasa, C.M. Ronckers, S. Caruso, E. Sugden,

L. Zadravec Zaletel, M. Muraca, V. Morsellino, A. Kienesberger, A.

Blondeel, D. Saraceno, M. Ortali, L.C.M. Kremer, R. Skinner, J. Roganovic,

F. Bagnasco, G.A. Levitt, M. De Rosa, M. Schrappe, L. Hjorth, R.

Ladenstein, PanCareSurFup, ENCCA Working Group, ExPo-r-Net Working

Group, The "Survivorship Passport" for childhood cancer survivors., Eur J

Cancer 102 (2018) 69–81. https://doi.org/10.1016/j.ejca.2018.07.006.

FIGURE 1 Participant responses to questions on awareness and prior hearing evaluation.

599
Participants who reported (a) having been informed or advised about the possibility of hearing loss and the need for hearing tests after completing
therapy and (b) having had a hearing evaluation after completing the therapy. Proportional Venn-Diagram depicting the relation between having
been informed or advised and having had a hearing evaluation.

Numbers represent the number (n) and percentage (%) of participants reporting yes to the respective question; (a) Informed/Advised, Were you
informed about hearing loss as a potential late effect of your treatment / Have you been advised to have your hearing checked after completing

your therapies? (b) Hearing evaluated, Has your hearing ever been checked after you finished your treatment? No/Don't know; Answered no or do
not know to both questions.

Abbreviations: n,   number.

FIGURE 2 Degree of hearing loss assessed with audiograms and
graded according to SIOP Boston ototoxicity scale, and responses of
questions on awareness with clinically relevant hearing loss (Grade
≥2).

(left) Degree of hearing loss according to SIOP Boston Ototoxicity Scale for participants with
available audiograms, N=83. No hearing loss, grade 0. Mild, grade 1. Moderate, grade 2. Severe,
≥ grade 3.

(right) Participants with clinically relevant hearing loss (SIOP Boston ototoxicity scale ≥2, n=36)
who completed the baseline questionnaire and status on information/advice received on hearing
loss (yes/no), hearing evaluated after therapy end (yes/no), self-reported hearing loss (yes/no),
hearing difficulties in noisy environments (yes/no) and feeling of bad hearing (yes/no). 95%
Confidence intervals are displayed for those reporting "Yes".

[a], Participants with clinically relevant hearing loss who did not complete the baseline
questionnaire were excluded from this graphic (n=1).

Abbreviations: SIOP, International Society of Paediatric Oncology. n, number.

Supplementary FIGURE SF1 Flowchart illustrating the HEAR-study
population, depicting eligible survivors identified by the Swiss
Childhood Cancer Registry.

Abbreviations: ICCC-3, international classification of childhood cancer, edition 3. n,
number.

Supplementary TABLE S1 Demographic and clinical characteristics
of study population, stratified by response status.

	Total invited N=424	Completed questionnaire N=105	Did not respond to questionnaire N=319	p-value[a]	Cramér's V / Cohen's d[b]
	n (%)	*n (%)*	*n (%)*		
Sex				0.08	0.08
Female	199 (47)	57 (54)	142 (45)		
Male	225 (53)	48 (46)	177 (55)		
Age at study, years (Median, IQR)	29 (23-37)	32 (24-37)	29 (22-36)	0.03	0.24
18-25	148 (35)	33 (31)	115 (36)		
26-34	141 (33)	31 (30)	110 (34)		
35-57	135 (32)	41 (39)	94 (29)		
Year of diagnosis (Median, range)	1999 (1977-2019)	1998 (1977-2018)	2000 (1978-2019)	0.02	0.25
1977-1995	147 (35)	33 (31)	114 (36)		
1996-2003	153 (36)	39 (37)	114 (36)		
2004-2019	124 (29)	33 (31)	91 (29)		
Time since diagnosis, years (Median, IQR)	22 (16-30)	23 (19-32)	21 (16-29)	0.03	0.25
3-18	143 (34)	25 (24)	118 (37)		
19-26	144 (34)	40 (38)	104 (33)		
27-44	137 (32)	40 (38)	97 (30)		
Age at cancer diagnosis, years (Median, IQR)	9 (3.5-13)	8 (4-13)	9 (3-13)	0.87	0.02
≤5	147 (35)	33 (31)	114 (36)		
6-12	153 (36)	39 (37)	114 (36)		
13-20	124 (29)	33 (31)	91 (29)		
Diagnostic group of primary neoplasm (ICCC-3)				0.01	0.23
Leukemias (I)	8 (2)	0 (0)	8 (3)		
Lymphomas (II)	17 (4)	7 (7)	10 (3)		
CNS (III)	111 (26)	23 (22)	88 (28)		
Neuroblastoma (IV)	42 (10)	13 (12)	29 (9)		
Retinoblastoma (V)	15 (4)	3 (3)	12 (4)		
Renal tumors (VI)	30 (7)	2 (2)	28 (9)		
Hepatic tumors (VII)	11 (3)	4 (4)	7 (2)		
Malignant bone tumors (VIII)	71 (17)	24 (23)	47 (15)		
Soft tissue (IX)	67 (16)	22 (21)	45 (14)		
Germ cell tumors (X)	49 (12)	7 (7)	42 (13)		
Other (XI)	3 (1)	0 (0)	3 (1)		
Platinum Chemotherapy				0.50	0.10
No platinum chemotherapy	91 (21)	23 (22)	68 (21)		
Cisplatin	148 (35)	42 (40)	106 (33)		
Carboplatin	92 (22)	17 (16)	75 (24)		
Cisplatin & Carboplatin	78 (18)	21 (20)	57 (18)		
Unknown	15 (4)	2 (2)	13 (4)		
Cranial radiation				0.57	0.07
No cranial radiation	253 (60)	64 (61)	189 (59)		
<30 Gray	3 (1)	0 (0)	3 (1)		
≥30 Gray	165 (39)	41 (39)	124 (39)		
Unknown	3 (1)	0 (0)	3 (1)		

Abbreviations: n, number. IQR, Interquartile Range. ICCC-3, international classification

of childhood cancer, edition 3. CNS, central nervous system.

[a], p-values calculated from chi-square statistics for categorical variables and two-sided t-

test for continuous variables, comparing responders to non-responders.

[b], Effect sizes were calculated using Cramér's V for categorical and Cohen's d for

continuous variables.

Supplementary TABLE S2 Clinical risk factors for hearing loss in
childhood cancer survivors who participated in the HEAR-study
(N=105).

	Cranial radiation ≥30 Gray n (%)	No cranial radiation n (%)	Total n (%)
Cisplatin	4 (10)	38 (59)	42 (40)
Carboplatin	7 (17)	10 (16)	17 (16)
Cisplatin & Carboplatin	6 (15)	15 (23)	21 (20)
No platinum chemotherapy	23 (56)	0 (0)	23 (22)
Unknown	1 (2)	1 (2)	2 (2)
Total	41 (100)	64 (100)	105 (100)

648 **Supplementary TABLE S3** Calendar period of last completed
649 hearing test (n=40).

Year	Participants N=40 (n, (%))
<2020	12 (30)
2020-2022	13 (33)
Do not remember	15 (38)

651 Abbreviations: n, number.
652

654 **Supplementary TABLE S4** Characteristics of participants by
655 information status and factors associated with information status;
656 results from univariable logistic regressions.

	Informed/Advised yes N=46	Informed/Advised no or don't know know N=59	Univariable OR (95‰-CI) N=105	p-value
	n (%)	*n (%)*		
Sex				
Female	24 (52)	33 (56)	1.0	
Male	22 (48)	26 (44)	1.2 (0.5-2.5)	0.70
Median age at study (IQR; Range)	29 (22-35; 18-43)	34 (25-45; 19-57)	0.9 (0.9-1.0)	**<0.01**
Median years since diagnosis (IQR; Range)	20 (17-26; 4-43)	27 (22-34; 7-44)	0.9 (0.9-1.0)	**<0.01**
Median age at diagnosis (IQR; Range)	10 (4-14; 0-19)	7 (3-13; 0-19)	1.0 (1.0-1.1)	0.19
Year of diagnosis (IQR; Range)	2002 (1996-2005; 1979-2018)	1995 (1987-2000; 1977-2014)	1.1 (1.0-1.2)	**<0.01**
≤1995	11 (24)	30 (51)	3.3 (1.4-7.7)	**<0.01**
>1995	35 (76)	29 (49)		
Language region				0.20
French	11 (24)	21 (36)	1.0	
German	35 (76)	38 (64)	1.8 (0.7-4.2)	
Participant education				
Primary or secondary education	29 (63)	33 (56)	1.0	
Tertiary education	17 (37)	26 (44)	0.7 (0.3-1.6)	0.46
Maternal education[a]				
Primary or secondary education	29 (63)	47 (80)	1.0	
Tertiary education	16 (35)	11 (19)	2.4 (1.0-5.8)	**0.06**
Missing	1 (2)	1 (2)	NA	NA
Paternal education[a]				
Primary or secondary education	28 (61)	44 (75)	1.0	
Tertiary education	17 (37)	15 (25)	1.8 (0.8-4.1)	0.18
Missing	1 (2)	0 (0)	NA	NA
Migration background[a]				
No	29 (63)	35 (59)	1.0	
Yes	17 (37)	22 (37)	0.9 (0.4-2.1)	0.87
Missing	0 (0)	2 (3)	NA	NA
Late effects other than hearing loss				
No	9 (20)	24 (41)	1.0	
Yes	37 (80)	35 (59)	2.8 (1.2-6.9)	**0.02**
Self-reported hearing loss				
No	27 (59)	54 (92)	1.0	
Yes	19 (41)	5 (8)	7.6 (2.6-22.6)	**<0.01**
General information received on follow-up care				
No	24 (52)	43 (73)	1.0	
Yes	22 (48)	16 (27)	2.5 (1.1-5.6)	**0.03**
Regular visit of follow-up care				
No	20 (43)	38 (64)	1.0	
Yes	26 (57)	21 (36)	2.4 (1.1-5.2)	**0.03**
Treatment groups				
Cranial radiation ≥30 Gray only	3 (7)	20 (34)	1.0	
Platinum Chemotherapy only	32 (70)	31 (53)	6.9 (1.9-25.5)	**<0.01**
Both	11 (24)	6 (10)	12.2 (2.5-58.7)	**<0.01**
Missing	0	2 (3)	NA	NA

[a], People with missing maternal or paternal education, missing migration background

and missing cisplatin were excluded from the univariable logistic regression.

Abbreviations: N, number OR, Odds Ratio. CI, Confidence Interval. IQR, Interquartile

Range.

Supplementary TABLE S5 Characteristics of participants by status
of prior hearing evaluation; results from univariable logistic
regressions.
665

	Hearing evaluated yes N=40	Hearing evaluated no or didn't know N=65	Univariable OR (95%-CI) N=105	p-value
	n (%)	*n (%)*		
Sex				
Female	22 (55)	35 (54)	1.0	
Male	18 (45)	30 (46)	1.0 (0.4-2.1)	0.91
Median age at study (IQR; Range)	29 (24-35; 18-48)	34 (24-43; 19-57)	1.0 (0.9-1.0)	**0.036**
Median years since diagnosis (IQR; Range)	21 (17-26; 4-41)	26 (20-34; 4-44)	0.9 (0.9-1.0)	**0.013**
Median age at diagnosis (IQR; Range)	9 (3-14; 0-19)	8 (4-13; 0-19)	1.0 (1.0-1.1)	0.57
Year of diagnosis (IQR; Range)	2000 (1996-2005; 1981-2018)	1996 (1988-2002; 1977-2017)	1.1 (1.0-1.1)	**0.01**
≤1995	9 (23)	32 (49)	3.3 (1.4-8.1)	**<0.01**
>1995	31 (78)	33 (51)		
Language region				
French	11 (28)	21 (32)	1.0	
German	29 (73)	44 (68)	1.3 (0.5-3.0)	0.60
Participant education				
Primary or secondary education	27 (68)	35 (54)	1.0	
Tertiary education	13 (33)	30 (46)	0.6 (0.2-1.3)	0.17
Maternal education[a]				
Primary or secondary education	24 (60)	52 (80)	1.0	
Tertiary education	15 (38)	12 (18)	2.8 (1.1-6.8)	**0.03**
Missing	1 (3)	1 (2)	NA	NA
Paternal education[a]				
Primary or secondary education	25 (63)	47 (72)	1.0	
Tertiary education	14 (35)	18 (28)	1.5 (0.6-3.4)	0.38
Missing	1 (3)	0 (0)	NA	NA
Migration background[a]				
No	24 (60)	40 (62)	1.0	
Yes	16 (40)	23 (35)	1.2 (0.5-2.6)	0.72
Missing	0 (0)	2 (3)	NA	NA
Late effects other than hearing loss				
No	7 (18)	26 (40)	1.0	
Yes	33 (83)	39 (60)	3.1 (1.2-8.2)	**0.02**
Self-reported hearing loss				
No	27 (68)	54 (83)	1.0	
Yes	13 (33)	11 (17)	2.4 (0.9-6.0)	**0.07**
General information received on follow-up care				
No	20 (50)	47 (72)	1.0	
Yes	20 (50)	18 (28)	2.6 (1.1-6.0)	**0.02**
Information/advice received on hearing loss and hearing screening				
No	7 (18)	52 (80)	1.0	
Yes	33 (83)	13 (20)	18.9 (6.8-52.1)	**<0.01**
Regular visit of follow-up care				
No	18 (45)	40 (62)	1.0	
Yes	22 (55)	25 (38)	2.0 (0.9-4.3)	**0.10**
Treatment groups[a]				
Cranial radiation ≥30 Gray only	4 (10)	19 (29)	1.0	
Platinum Chemotherapy only	28 (70)	35 (54)	3.8 (1.2-12.5)	**0.03**
Both	8 (20)	9 (14)	4.2 (1.0-17.8)	**0.05**

Missing	0 (0)	2 (3)	NA	NA

[a], People with missing maternal or paternal education, missing migration background

and missing platin status were excluded from the univariable logistic regression.

Abbreviations: N, number OR, Odds Ratio. CI, Confidence Interval. IQR, Interquartile

Range.

Supplementary TABLE S6 Questions on late effects, hearing loss,
information provision, awareness of hearing loss, and
sociodemographic characteristics in from the HEAR-study (translated
into English).

Variable	Question in questionnaire	Answer options
Presence of late effects	Are you suffering from a late effect of your previous cancer or its treatment?	Yes; no
Self-reported hearing loss	What late effects do you suffer from?	Open
General information received regarding follow-up care	Have you received written or verbal information from your pediatric oncologists regarding follow-up care?	Yes; no; don't know
Information status	Have you been informed that hearing impairment or hearing loss is possible after completion of therapy?	Yes; no; don't know
	Have you been advised to have your hearing checked after completing your therapy?	Yes; no; don't know
Regular visit of follow-up care	Do you still go to regular check-ups or follow-up care for your cancer?	Yes; no
Prior hearing evaluation	Has your hearing been checked after you have completed your cancer treatment?	Yes; no; don't know
Participant education	What is the highest level of education you have completed?	Obligatory; vocational training; high school; technical college; university
Education mother/father	What is your mother's/father's highest level of education?	Obligatory; vocational training; high school; technical college; university
Birthplace mother/father	In which country was your mother/father born?	Switzerland; don't know; other
Feeling of bad hearing	Do you sometimes have the feeling of not hearing well?	Yes, often; yes, sometimes; no
Hearing difficulties in noisy environments	Do you have problems following conversations in background noise, in a group, in a restaurant or with background music?	Yes; no

676
677